Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(-)-Virginiamycin M2 is a type A streptogramin antibiotic produced by Streptomyces virginiae. It is a mixture of closely related compounds, with the main component being virginiamycin M1. This antibiotic is characterized by its antimicrobial activity against a range of bacteria, including both Gram-positive and some Gram-negative species. Its mechanism of action involves the inhibition of protein synthesis in bacteria, ultimately leading to their death.

21102-49-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 21102-49-8 Structure
  • Basic information

    1. Product Name: (-)-Virginiamycin M2
    2. Synonyms: (-)-Virginiamycin M2;(27R)-26,27-Dihydrovirginiamycin M2;Ostreogrycin G;Pristinamycin IIB;Virginiamycin M2;Volpristin
    3. CAS NO:21102-49-8
    4. Molecular Formula: C28H37 N3 O7
    5. Molecular Weight: 527.6093
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 21102-49-8.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 809.5°Cat760mmHg
    3. Flash Point: 443.3°C
    4. Appearance: /
    5. Density: 1.25g/cm3
    6. Vapor Pressure: 1.11E-27mmHg at 25°C
    7. Refractive Index: 1.575
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. PKA: 13.18±0.70(Predicted)
    11. CAS DataBase Reference: (-)-Virginiamycin M2(CAS DataBase Reference)
    12. NIST Chemistry Reference: (-)-Virginiamycin M2(21102-49-8)
    13. EPA Substance Registry System: (-)-Virginiamycin M2(21102-49-8)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 21102-49-8(Hazardous Substances Data)

21102-49-8 Usage

Uses

Used in Veterinary Medicine:
(-)-Virginiamycin M2 is used as a preventive and treatment agent for infections in livestock. Its broad-spectrum antimicrobial activity makes it effective against various bacterial infections that can affect the health and productivity of animals in the industry.
Used in Human Medicine (with limitations):
While (-)-Virginiamycin M2 has shown potential for use in human medicine, its application is limited due to concerns about the development of antibiotic resistance and potential side effects. Further research and development are necessary to explore its potential uses in treating human infections while mitigating these risks.

Check Digit Verification of cas no

The CAS Registry Mumber 21102-49-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,1,0 and 2 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 21102-49:
(7*2)+(6*1)+(5*1)+(4*0)+(3*2)+(2*4)+(1*9)=48
48 % 10 = 8
So 21102-49-8 is a valid CAS Registry Number.
InChI:InChI=1/C28H37N3O7/c1-17(2)26-19(4)7-8-24(34)29-10-5-6-18(3)12-21(32)13-22(33)14-25-30-23(16-37-25)27(35)31-11-9-20(15-31)28(36)38-26/h5-8,12,16-17,19-21,26,32H,9-11,13-15H2,1-4H3,(H,29,34)/b6-5+,8-7+,18-12+/t19-,20+,21-,26-/m1/s1

21102-49-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name Volpristin [INN]

1.2 Other means of identification

Product number -
Other names UNII-18UAN5144E

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:21102-49-8 SDS

21102-49-8Downstream Products

21102-49-8Relevant articles and documents

Synthetic group A streptogramin antibiotics that overcome Vat resistance

Biel, Justin T.,Borrelli, Kenneth,Brilot, Axel F.,Chaires, Hector A.,Chesneau, Olivier,Chow, David,Fraser, James S.,Jacobson, Matthew P.,Ji, Kaijie,Lee, D. John,Li, Qi,Murray, Beverly,Park, Jesslyn E.,Pellegrino, Jenna,Seiple, Ian B.,Shinabarger, Dean,Tran, Arthur A.,Wang, Ruoxi,Wolfe, Cindy,Zhang, Na,van Zundert, Gydo,Mühle, Estelle

, p. 145 - 150 (2020)

Natural products serve as chemical blueprints for most antibiotics in clinical use. The evolutionary process by which these molecules arise is inherently accompanied by the co-evolution of resistance mechanisms that shorten the clinical lifetime of any given class of antibiotics1. Virginiamycin acetyltransferase (Vat) enzymes are resistance proteins that provide protection against streptogramins2, potent antibiotics against Gram-positive bacteria that inhibit the bacterial ribosome3. Owing to the challenge of selectively modifying the chemically complex, 23-membered macrocyclic scaffold of group A streptogramins, analogues that overcome the resistance conferred by Vat enzymes have not been previously developed2. Here we report the design, synthesis, and antibacterial evaluation of group A streptogramin antibiotics with extensive structural variability. Using cryo-electron microscopy and forcefield-based refinement, we characterize the binding of eight analogues to the bacterial ribosome at high resolution, revealing binding interactions that extend into the peptidyl tRNA-binding site and towards synergistic binders that occupy the nascent peptide exit tunnel. One of these analogues has excellent activity against several streptogramin-resistant strains of Staphylococcus aureus, exhibits decreased rates of acetylation in vitro, and is effective at lowering bacterial load in a mouse model of infection. Our results demonstrate that the combination of rational design and modular chemical synthesis can revitalize classes of antibiotics that are limited by naturally arising resistance mechanisms.

STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF

-

, (2020/12/30)

Disclosed herein, inter alia, are streptogramin compounds, compositions, and methods of use thereof. A method of treating an infectious disease, the method including administering to a subject in need thereof an effective amount of a compound described herein.

METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF

-

, (2019/02/15)

Disclosed herein, inter alia, are methods of making and using streptogramin compositions.

Modular, Scalable Synthesis of Group A Streptogramin Antibiotics

Li, Qi,Seiple, Ian B.

, p. 13304 - 13307 (2017/10/05)

Streptogramin antibiotics are used clinically to treat multidrug-resistant bacterial infections, but their poor physicochemical properties and narrow spectra of activity have limited their utility. New methods to chemically modify streptogramins would enable structural optimization to overcome these limitations as well as to combat growing resistance to the class. Here we report a modular, scalable synthesis of group A streptogramin antibiotics that proceeds in 6-8 linear steps from simple chemical building blocks. We have applied our route to the synthesis of four natural products in this class including two that have never before been accessed by fully synthetic routes. We anticipate that this work will lead to the discovery of new streptogramin antibiotics that overcome previous limitations of the class.

Total synthesis of (-)-virginiamycin m2: Application of crotylsilanes accessed by enantioselective Rh(II) or Cu(I) promoted carbenoid Si-H insertion

Wu, Jie,Panek, James S.

experimental part, p. 9900 - 9918 (2012/03/08)

A stereoselective synthesis of the antibiotic (-)-virginiamycin M 2 is detailed. A convergent strategy was utilized that proceeded in 10 steps (longest linear sequence) from enantioenriched silane (S)-15. This reagent, which was prepared via a Rh(II)- or Cu(I)-catalyzed carbenoid Si-H insertion, was used to introduce the desired olefin geometry and stereocenters of the C1-C5 propionate subunit. A modified Negishi cross-coupling or an efficient alkoxide-directed titanium-mediated alkyne-alkyne reductive coupling strategy was utilized to assemble the trisubstituted (E,-E)-diene. An underutilized late-stage SmI2-mediated macrocyclization was employed to construct the 23-membered macrocycle scaffold of the natural product (Figure presented).

Total synthesis of (-)-virginiamycin M2 using second-generation vinylogous urethane chemistry

Schlessinger,Li

, p. 3301 - 3302 (2007/10/03)

Antibiotics known as the virginiamycins consist of two groups-polyunsaturated macrolactones (type A) and peptidic macrolactones (type B). Mixtures of type A and type B virginiamycins exhibit very high potency against a variety of bacteria. Total syntheses

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 21102-49-8